Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (September 2022)
36 slides from Arovella Therapeutics's investor presentation, Sep 26, 2022
Slide 1: Strategic Collaboration
For personal use only ASX: ALA Strategic Collaboration September 2022
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). For pers
Slide 3: Arovella Therapeutics Highlights
Arovella Therapeutics Highlights For personal use only World Leading Partners Allogeneic Platform, Two Targets Acquiring New Technologies Arovella licenced its iNKT Cell Therapy Arovella is developing off the shelf cell Arovella continues to focus on sourcing, Platform from Imperial College London a
Slide 4: Introduction to Imugene
INTRODUCTION TO IMUGENE Imugene is a biotech company headquartered in Australia and publicly traded on the Australian Securities Exchange (ASX:IMU) For personal use only Licensed extensive Licensed onCARlytics B cell portfolio and from City of Hope invented HER-Vaxx Clinical Trial Leslie Chong platf
Slide 5: CAR19-iNKT + CF33-CD19
For personal use only CAR19-iNKT + CF33-CD19 An off-the-shelf cell therapy and oncolytic virus combination to mark and destroy solid tumours © Copyright Arovella Therapeutics Ltd 2022
Slide 6: Combining CAR19-iNKT Cells and CF33-CD19 (onCARlytics)
Combing CAR19-iNKT Cells and CF33-CD19 (onCARlytics) CF33 is an oncolytic virus that targets tumour CAR19-iNKT cells are very potent and are For personal use only cells and not healthy cells rapidly activated to kill CD19 expressing The virus was developed at City of Hope by cancer cells Profe
Slide 7: Expanding ALA-101's Utility
Expanding ALA-101’s Utility For personal use only We expect CAR19-iNKT cells to be effective against blood cancers that naturally produce CD19 Combining CF33-CD19 with CAR19- iNKT cells opens up the possibility of treating a range of solid tumours 7 © Copyright Arovella Therapeutics Ltd 2022
Slide 8: What is the Mechanism of Action?
What is the Mechanism of Action? For personal use only 8 © Copyright Arovella Therapeutics Ltd 2022
Slide 9: Arovella Therapeutics Cell Therapy Pipeline
Arovella Therapeutics Cell Therapy Pipeline For personal use only Cell Therapy INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE2/31 PARTNER ALA-101 CD19 expressing CD19 Expressing Lymphoma (CAR19-iNKT) cancers ALA-101 + Solid tumours Solid Tumours CF33-CD19 ALA-104 Multiple Multiple Myeloma & Solid Tu
Slide 10: ALA-101 + CF33-CD19 Upcoming Milestones
ALA-101 + CF33-CD19 Upcoming Milestones Activity Target Date For personal use only Finalise Agreement and Study Setup Q4 2022 Complete in vitro (test tube) study to assess CAR19-iNKT Q1 2023 cell activity against CD19 producing cancer cells Complete in vivo (mouse) studies to assess CAR19-iNKT
Slide 11: Arovella Company Overview
Arovella Company Overview Financial Snapshot ASX CODE ALA 35,000,000 $0.080 For personal use only ALA Price and Volume - 12 Months1 Market capitalisation1 $18.1 million 30,000,000 $0.070 Shares on issue 669.8 million 25,000,000 $0.060 52-week low / high $0.020 / $0.057 20,000,000 $0.050 Cash (June 3
Slide 12: Upcoming Milestones FY23
Upcoming Milestones FY23 Activity for Arovella (now to June 2023) Therapy Complete (CY) For personal use only Strategic planning outcomes Company Wide Q4 2022 Finalise CAR19-iNKT and onCARlytics Agreement and study setup ALA-101/CF33-CD19 Q4 2022 Complete in vitro (test tube) study to assess C
Slide 13: Cancer Continues to be a Major Health Issue
Cancer Continues to be a Major Health Issue For personal use only Worldwide, an estimated Cancer is a leading The global cancer 19.3 million new cancer cause of death therapeutics market is cases (18.1 million worldwide, accounting expected to reach $366 excluding non-melanoma for nearly 10 million
Slide 14: Cell Therapy Revolution to Treat Cancer
Cell Therapy Revolution to Treat Cancer Recent Media Attention – Feb & May 2022 For personal use only 14 © Copyright Arovella Therapeutics Ltd 2022
Slide 15: iNKT Cell Therapy Platform
iNKT Cell Therapy Platform For personal use only © Copyright Arovella Therapeutics Ltd 2022
Slide 16: CAR-iNKT Cell Therapy Production and Advantages
CAR-iNKT Cell Therapy Production and Advantages CAR-iNKT Production Steps For personal use only 1. Blood Collection and Immune Cell Harvesting 2. Isolation and Re-programming of iNKT Cells 3. Multiplication of Cells 4. Cells are Administered to the Patient CAR-iNKT Cell Advantages 1. Preclinical evi
Slide 17: CAR-iNKT Cells are Engineered to Enhance Activity
CAR-iNKT Cells are Engineered to Enhance Activity APPROVED CAR-NK CELLS CAR-iNKT For personal use only CAR-T CELLS CELLS Subpopulation of T cells with NK cell properties Intrinsic anti-cancer receptor (dual targeting) Naturally suppress GVHD Allogeneic, ‘off-the-shelf’ dosing
Slide 18: How does the CAR-iNKT Cell Therapy Platform Work?
How does the CAR-iNKT Cell Therapy Platform Work? 1. iNKT cells contain 2. We introduce a 3. CAR-iNKT cells are 4. The cancer cell is For personal use only an iTCR that chimeric antigen activated after they attach killed, and other naturally assists receptor (CAR) to target to the cancer cells, comp
Slide 19: CAR19-iNKT (ALA-101)
For personal use only CAR19-iNKT (ALA-101) An off-the-shelf cell therapy for CD19 expressing cancers © Copyright Arovella Therapeutics Ltd 2022
Slide 20: ALA-101: CAR19-iNKT Cells to Treat Blood Cancers
ALA-101: CAR19-iNKT Cells to Treat Blood Cancers CAR19-iNKT Outperforms Conventional Therapies For personal use only ALA-101 is anticipated to be an effective, Faster Killing of Cancer Spontaneous Secondary off-the-shelf cell therapy for the Cells That Have CD1d Remission treatment of CD19 express
Slide 21: DKK1-CAR-iNKT (ALA-104)
For personal use only DKK1-CAR-iNKT (ALA-104) An off-the-shelf cell therapy for multiple myeloma (blood cancer) and potentially solid tumours © Copyright Arovella Therapeutics Ltd 2022
Slide 22: A Novel Cancer Target – DKK1 Peptide (ALA-104)
A Novel Cancer Target – DKK1 Peptide (ALA-104) DKK1 is a secreted protein that functions as a negative regulator of the WNT signaling For personal use only pathway DKK1 is overproduced in numerous cancer types and DKK1 peptides are loaded onto immune complexes and presented at the surface of can
Slide 23: Development of DKK1-CAR to Date
Development of DKK1-CAR to Date The DKK1 mAb was developed at MD For personal use only Anderson and can be incorporated Already Completed Arovella To Complete into a chimeric antigen receptor (CAR) The DKK1 peptide-targeting mAb has demonstrated activity against multiple myeloma and breast cance
Slide 24: DKK1-CAR-T Cell Activity in Multiple Myeloma
DKK1-CAR-T Cell Activity in Multiple Myeloma DKK1-CAR-T cells were tested in three different animal models for multiple myeloma, displaying robust activity in For personal use only all standard models Model 1 – U266 Model 2 – KMS-12-BM Model 3 – MM.1S 100 100 100 S u r v iv a l p e r c e n ta g e S
Slide 25: DKK1-CAR-T Preclinical Safety
DKK1-CAR-T Preclinical Safety Prof Qing Yi at Houston Methodist has demonstrated: For personal use only • They only kill cells that have the DKK1 peptide presented in an HLA-A2 complex on their surface • They do not kill healthy blood cells • That the DKK1-CAR-T cells are considered safe using in vi
Slide 26: The Inventor – Professor Qing Yi
The Inventor – Professor Qing Yi Professor Qing Yi is a trained medical immunologist with over 25 years of experience. For personal use only He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers. He has trained at the Karolin
Slide 27: Arovella Team
For personal use only Arovella Team © Copyright Arovella Therapeutics Ltd 2022
Slide 28: Arovella Has a World Class Team
Arovella Has a World Class Team Dr. Elizabeth Stoner Dr. Michael Baker Dr. Debora Barton For personal use only INTERIM CHAIRPERSON CEO & MANAGING DIRECTOR DIRECTOR Dr. Stoner is a distinguished biopharma Dr. Baker has over 15 years experience in Dr. Barton has over 20 years of oncology executive, wh
Slide 29: Thank You
For personal use only Thank You Dr Michael Baker CEO & Managing Director Email: mbaker@arovella.com Mobile: +61 403 468 187 © Copyright Arovella Therapeutics Ltd 2022
Slide 30: Appendices
For personal use only Appendices © Copyright Arovella Therapeutics Ltd 2022
Slide 31: Preclinical In Vivo Safety Evaluation of CAR19-iNKT cells
Preclinical In Vivo Safety Evaluation of CAR19-iNKT cells CAR19-iNKT cells do not elicit adverse effects in For personal use only preclinical mouse tumour models No body weight loss Mice Body Weight Data in mouse models did not show off-target effects No histological changes in normal tissues
Slide 32: iNKT Cells Protect Against Graft Versus Host Disease
iNKT Cells Protect Against Graft Versus Host Disease 2017 2017 2016 2015 2015 Conventional CAR-T cell therapies For personal use only are limited to autologous products due to the potential for acute graft versus host disease (GVHD) Front Immunol 2017 July 31;8:900 Leukemia 2017 Apr;31(4):903-912
Slide 33: Use of iNKT Cells in Clinical Trials
Use of iNKT Cells in Clinical Trials 2020 2017 2013 2012 2011 iNKT cells, in the presence and For personal use only absence of CARs, have been used in numerous clinical trials against a range of tumour types, including blood cancers and solid tumours Nat Med Clin Cancer Res. Blood J Clin Immunol.
Slide 34: DKK1's Role in Cancer
DKK1’s Role in Cancer 2021 2019 2019 2019 2018 DKK1 is overproduced in a For personal use only number of cancer types, including pancreatic, oesophageal, hepatocellular, breast, lung cancer and multiple myeloma Oncogene, Annals of translational Oncogene, American journal of Clinical & experimental
Slide 35: Understanding Immunology and Cell Therapy
Understanding Immunology and Cell Therapy Antigen = Any substance that induces the immune system to produce antibodies against it is called an antigen. Any foreign invaders, such as pathogens (bacteria and viruses), chemicals, toxins, and pollens, can be antigens. For personal use only CAR = Chi
Slide 36: Committed to helping people live longer and healthier lives
For personal use only Committed to helping people live longer and healthier lives Patient-Centric It starts with the end in mind. In our case, it is our patients. At Arovella, we are invested in making a positive difference in helping patients live longer and healthier lives. Creating a brighter fut
Arovella Therapeutics — Investor Presentation (September 2022) on 6ix